$0.29
7.57% yesterday
Nasdaq, May 20, 09:49 pm CET
ISIN
US29350E1047
Symbol
RENB
Sector
Industry

Renovaro Stock price

$0.29
-0.11 27.76% 1M
-0.21 42.40% 6M
-0.55 65.27% YTD
-0.68 70.08% 1Y
-5.97 95.36% 3Y
-3.45 92.24% 5Y
-5.79 95.23% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.03 8.11%
ISIN
US29350E1047
Symbol
RENB
Sector
Industry

Key metrics

Market capitalization $49.95m
Enterprise Value $55.35m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.53
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-19.90m
Free Cash Flow (TTM) Free Cash Flow $-8.50m
Cash position $1.63m
EPS (TTM) EPS $-0.47
Short interest 4.47%
Show more

Is Renovaro a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Financial data from Renovaro

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.13 0.13
8% 8%
-
-0.13 -0.13
8% 8%
-
- Selling and Administrative Expenses 19 19
16% 16%
-
- Research and Development Expense 0.89 0.89
73% 73%
-
-20 -20
23% 23%
-
- Depreciation and Amortization 0.13 0.13
8% 8%
-
EBIT (Operating Income) EBIT -20 -20
23% 23%
-
Net Profit -75 -75
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about Renovaro directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Renovaro Stock News

Neutral
GlobeNewsWire
7 days ago
New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it ...
Neutral
GlobeNewsWire
8 days ago
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership ma...

Company Profile

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Head office United States
CEO David Weinstein
Employees 25
Founded 2011
Website renovarobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today